Bydureon BCise FDA Approval History
FDA Approved: Yes (First approved October 20, 2017)
Brand name: Bydureon BCise
Generic name: exenatide
Dosage form: Extended-Release Injectable Suspension
Company: AstraZeneca
Treatment for: Type 2 Diabetes
Bydureon BCise (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients with type 2 diabetes.
Development timeline for Bydureon BCise
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.